Identification

Name
Pramipexole
Accession Number
DB00413  (APRD00156)
Type
Small Molecule
Groups
Approved, Investigational
Description

Pramipexole is a medication indicated for treating Parkinson's disease and restless legs syndrome (RLS). It is also sometimes used off-label as a treatment for cluster headache or to counteract the problems with low libido experienced by some users of SSRI antidepressant drugs. Pramipexole has shown robust effects on pilot studies in bipolar disorder. Pramipexole is classified as a non-ergoline dopamine agonist.

Structure
Thumb
Synonyms
  • (-)-Pramipexole
  • (S)-N  6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine
  • 2,6-Benzothiazolediamine, 4,5,6,7-tetrahydro-N(sup 6)-propyl-, (S)-
  • Pramipexol
  • Pramipexole
  • Pramipexolum
External IDs
PNU 98528 / SND 919 Cl 2Y / SUD 919 CL 24 / U 98528 E
Product Ingredients
IngredientUNIICASInChI Key
Pramipexole dihydrochloride monohydrate3D867NP06J 191217-81-9APVQOOKHDZVJEX-QTPLPEIMSA-N
Pramipexole hydrochloride4R2HD0M28N 104632-25-9QMNWXHSYPXQFSK-KLXURFKVSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act PramipexoleTablet0.25 mgOralActavis Pharma Company2009-04-15Not applicableCanada
Act PramipexoleTablet0.5 mgOralActavis Pharma Company2009-04-15Not applicableCanada
Act PramipexoleTablet1.5 mgOralActavis Pharma Company2009-04-15Not applicableCanada
Act PramipexoleTablet1 mgOralActavis Pharma Company2009-04-15Not applicableCanada
Auro-pramipexoleTablet0.125 mgOralAuro Pharma Inc2014-04-29Not applicableCanada
Auro-pramipexoleTablet1 mgOralAuro Pharma Inc2014-04-29Not applicableCanada
Auro-pramipexoleTablet0.5 mgOralAuro Pharma Inc2014-04-29Not applicableCanada
Auro-pramipexoleTablet1.5 mgOralAuro Pharma Inc2014-04-29Not applicableCanada
Auro-pramipexoleTablet0.25 mgOralAuro Pharma Inc2014-04-29Not applicableCanada
Ava-pramipexoleTablet1.0 mgOralAvanstra Inc2011-09-192014-08-21Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-pramipexoleTablet0.75 mgOralApotex CorporationNot applicableNot applicableCanada
Apo-pramipexoleTablet0.25 mgOralApotex Corporation2007-02-26Not applicableCanada
Apo-pramipexoleTablet1.5 mgOralApotex Corporation2007-02-26Not applicableCanada
Apo-pramipexoleTablet0.5 mgOralApotex Corporation2007-02-26Not applicableCanada
Apo-pramipexoleTablet0.125 mgOralApotex CorporationNot applicableNot applicableCanada
Apo-pramipexoleTablet1.0 mgOralApotex Corporation2007-02-26Not applicableCanada
PramipexoleTablet.75 mg/1OralCamber Pharmaceuticals2015-08-01Not applicableUs
PramipexoleTablet.25 mg/1OralCaraco Pharmaceutical Laboratories, Ltd.2013-05-23Not applicableUs
PramipexoleTablet1.5 mg/1OralAv Kare, Inc.2016-07-27Not applicableUs
PramipexoleTablet.75 mg/1OralCaraco Pharmaceutical Laboratories, Ltd.2013-05-23Not applicableUs
International/Other Brands
Glepark (Glenmark) / Medopexol (Medochemie) / Miramel (Clonmel) / Miraper (Specifar) / Mirapexin (Boehringer Ingelheim) / Pexola (Boehringer Ingelheim) / Sifrol (Boehringer Ingelheim) / Sifrol ER (Boehringer Ingelheim)
Categories
UNII
83619PEU5T
CAS number
104632-26-0
Weight
Average: 211.327
Monoisotopic: 211.114318249
Chemical Formula
C10H17N3S
InChI Key
FASDKYOPVNHBLU-ZETCQYMHSA-N
InChI
InChI=1S/C10H17N3S/c1-2-5-12-7-3-4-8-9(6-7)14-10(11)13-8/h7,12H,2-6H2,1H3,(H2,11,13)/t7-/m0/s1
IUPAC Name
(6S)-N6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine
SMILES
CCCN[[email protected]]1CCC2=C(C1)SC(N)=N2

Pharmacology

Indication

For the treatment of signs and symptoms of idiopathic Parkinson's disease

Structured Indications
Pharmacodynamics

Pramipexole is a nonergot dopamine agonist with high relative in vitro specificity and full intrinsic activity at the D2 subfamily of dopamine receptors, binding with higher affinity to D3 than to D2 or D4 receptor subtypes. The relevance of D3 receptor binding in Parkinson's disease is unknown. The precise mechanism of action of Pramipexole as a treatment for Parkinson's disease is unknown, although it is believed to be related to its ability to stimulate dopamine receptors in the striatum. This conclusion is supported by electrophysiologic studies in animals that have demonstrated that Pramipexole influences striatal neuronal firing rates via activation of dopamine receptors in the striatum and the substantia nigra, the site of neurons that send projections to the striatum.

Mechanism of action

The precise mechanism of action of Pramipexole as a treatment for Parkinson's disease is unknown, although it is believed to be related to its ability to stimulate dopamine receptors in the striatum.

TargetActionsOrganism
AD(3) dopamine receptor
agonist
Human
AD(2) dopamine receptor
agonist
Human
AD(4) dopamine receptor
agonist
Human
UAlpha-2B adrenergic receptor
unknown
Human
U5-hydroxytryptamine receptor 1A
unknown
Human
U5-hydroxytryptamine receptor 1D
unknown
Human
UAlpha-2A adrenergic receptor
partial agonist
Human
U5-hydroxytryptamine receptor 1B
unknown
Human
U5-hydroxytryptamine receptor 2A
unknown
Human
U5-hydroxytryptamine receptor 2B
unknown
Human
U5-hydroxytryptamine receptor 2C
unknown
Human
UAlpha-2C adrenergic receptor
unknown
Human
UD(1A) dopamine receptor
unknown
Human
UD(1B) dopamine receptor
unknown
Human
Absorption

Rapid. Absolute bioavailability is greater than 90%, indicating that pramipexole is well absorbed and undergoes little presystemic metabolism. Food does not affect the extent of absorption.

Volume of distribution
  • 500 L
Protein binding

About 15% bound to plasma proteins.

Metabolism

No metabolites have been identified in plasma or urine.

Route of elimination

Urinary excretion is the major route of pramipexole elimination, with 90% of a pramipexole dose recovered in urine, almost all as unchanged drug. Nonrenal routes may contribute to a small extent to pramipexole elimination, although no metabolites have been identified in plasma or urine.

Half life

8 hours

Clearance
  • renal cl=400 mL/min
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7-Nitroindazole7-Nitroindazole may increase the sedative activities of Pramipexole.Experimental
AcebutololThe risk or severity of adverse effects can be increased when Pramipexole is combined with Acebutolol.Approved
AcepromazineAcepromazine may increase the sedative activities of Pramipexole.Approved, Vet Approved
AceprometazineAceprometazine may increase the sedative activities of Pramipexole.Approved
AdipiplonAdipiplon may increase the sedative activities of Pramipexole.Investigational
AgomelatineAgomelatine may increase the sedative activities of Pramipexole.Approved, Investigational
AldesleukinThe risk or severity of adverse effects can be increased when Pramipexole is combined with Aldesleukin.Approved
AlfaxaloneAlfaxalone may increase the sedative activities of Pramipexole.Vet Approved
AlfentanilAlfentanil may increase the sedative activities of Pramipexole.Approved, Illicit
AliskirenThe risk or severity of adverse effects can be increased when Pramipexole is combined with Aliskiren.Approved, Investigational
AllopregnanoloneAllopregnanolone may increase the sedative activities of Pramipexole.Investigational
AlphacetylmethadolAlphacetylmethadol may increase the sedative activities of Pramipexole.Experimental, Illicit
AlphaprodineAlphaprodine may increase the sedative activities of Pramipexole.Illicit
AlprazolamAlprazolam may increase the sedative activities of Pramipexole.Approved, Illicit, Investigational
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Pramipexole.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Pramipexole is combined with Amiloride.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Pramipexole.Approved, Investigational
AmisulprideAmisulpride may increase the sedative activities of Pramipexole.Approved, Investigational
AmitriptylineAmitriptyline may increase the sedative activities of Pramipexole.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Pramipexole is combined with Amlodipine.Approved
AmobarbitalAmobarbital may increase the sedative activities of Pramipexole.Approved, Illicit
AmoxapineAmoxapine may increase the sedative activities of Pramipexole.Approved
AmperozideAmperozide may increase the sedative activities of Pramipexole.Experimental
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Pramipexole.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Pramipexole is combined with Amyl Nitrite.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Pramipexole.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Pramipexole is combined with Apraclonidine.Approved
AripiprazoleAripiprazole may increase the sedative activities of Pramipexole.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Pramipexole.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Pramipexole.Approved, Investigational
ArticaineArticaine may increase the sedative activities of Pramipexole.Approved
AsenapineAsenapine may increase the sedative activities of Pramipexole.Approved
AtenololThe risk or severity of adverse effects can be increased when Pramipexole is combined with Atenolol.Approved
AzaperoneAzaperone may increase the sedative activities of Pramipexole.Vet Approved
AzelastineAzelastine may increase the sedative activities of Pramipexole.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Pramipexole is combined with Azilsartan medoxomil.Approved
BaclofenBaclofen may increase the sedative activities of Pramipexole.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Pramipexole.Experimental
BarbitalBarbital may increase the sedative activities of Pramipexole.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Pramipexole.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Pramipexole is combined with Benazepril.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Pramipexole is combined with Bendroflumethiazide.Approved
BenperidolBenperidol may increase the sedative activities of Pramipexole.Investigational
BenzocaineBenzocaine may increase the sedative activities of Pramipexole.Approved
Benzyl alcoholBenzyl alcohol may increase the sedative activities of Pramipexole.Approved
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Pramipexole.Approved, Withdrawn
BetaxololThe risk or severity of adverse effects can be increased when Pramipexole is combined with Betaxolol.Approved
BisoprololThe risk or severity of adverse effects can be increased when Pramipexole is combined with Bisoprolol.Approved
BlonanserinThe therapeutic efficacy of Pramipexole can be decreased when used in combination with Blonanserin.Approved
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Pramipexole.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Pramipexole is combined with Bretylium.Approved
BrexpiprazoleBrexpiprazole may increase the sedative activities of Pramipexole.Approved
BrimonidineBrimonidine may increase the sedative activities of Pramipexole.Approved
BromazepamBromazepam may increase the sedative activities of Pramipexole.Approved, Illicit
BromisovalBromisoval may increase the sedative activities of Pramipexole.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Pramipexole.Approved, Investigational
BromperidolBromperidol may increase the sedative activities of Pramipexole.Investigational
BrompheniramineBrompheniramine may increase the sedative activities of Pramipexole.Approved
BrotizolamBrotizolam may increase the sedative activities of Pramipexole.Approved, Withdrawn
BumetanideThe risk or severity of adverse effects can be increased when Pramipexole is combined with Bumetanide.Approved
BupivacaineBupivacaine may increase the sedative activities of Pramipexole.Approved, Investigational
BuprenorphineBuprenorphine may increase the sedative activities of Pramipexole.Approved, Illicit, Investigational, Vet Approved
BupropionThe serum concentration of Pramipexole can be increased when it is combined with Bupropion.Approved
BuspironeBuspirone may increase the sedative activities of Pramipexole.Approved, Investigational
ButabarbitalButabarbital may increase the sedative activities of Pramipexole.Approved, Illicit
ButacaineButacaine may increase the sedative activities of Pramipexole.Vet Approved
ButalbitalButalbital may increase the sedative activities of Pramipexole.Approved, Illicit
ButambenButamben may increase the sedative activities of Pramipexole.Approved
ButethalButethal may increase the sedative activities of Pramipexole.Approved, Illicit
ButorphanolButorphanol may increase the sedative activities of Pramipexole.Approved, Illicit, Vet Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Pramipexole is combined with Canagliflozin.Approved
CandesartanThe risk or severity of adverse effects can be increased when Pramipexole is combined with Candesartan.Approved
CanertinibCanertinib may increase the sedative activities of Pramipexole.Investigational
CaptoprilThe risk or severity of adverse effects can be increased when Pramipexole is combined with Captopril.Approved
CarbamazepineCarbamazepine may increase the sedative activities of Pramipexole.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Pramipexole.Approved
CarbinoxamineCarbinoxamine may increase the sedative activities of Pramipexole.Approved
CarfentanilCarfentanil may increase the sedative activities of Pramipexole.Illicit, Vet Approved
CariprazineThe therapeutic efficacy of Pramipexole can be decreased when used in combination with Cariprazine.Approved
CarisoprodolCarisoprodol may increase the sedative activities of Pramipexole.Approved
CarteololThe risk or severity of adverse effects can be increased when Pramipexole is combined with Carteolol.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Pramipexole is combined with Carvedilol.Approved, Investigational
CetirizineCetirizine may increase the sedative activities of Pramipexole.Approved
Chloral hydrateChloral hydrate may increase the sedative activities of Pramipexole.Approved, Illicit, Vet Approved
ChlordiazepoxideChlordiazepoxide may increase the sedative activities of Pramipexole.Approved, Illicit
ChlormezanoneChlormezanone may increase the sedative activities of Pramipexole.Approved, Withdrawn
ChloroprocaineChloroprocaine may increase the sedative activities of Pramipexole.Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Pramipexole is combined with Chlorothiazide.Approved, Vet Approved
ChlorphenamineChlorphenamine may increase the sedative activities of Pramipexole.Approved
ChlorpromazineChlorpromazine may increase the sedative activities of Pramipexole.Approved, Vet Approved
ChlorprothixeneChlorprothixene may increase the sedative activities of Pramipexole.Approved, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Pramipexole is combined with Chlorthalidone.Approved
ChlorzoxazoneChlorzoxazone may increase the sedative activities of Pramipexole.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Pramipexole is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Pramipexole.Approved
CimetidineThe serum concentration of Pramipexole can be increased when it is combined with Cimetidine.Approved
CinchocaineCinchocaine may increase the sedative activities of Pramipexole.Approved, Vet Approved
ClemastineClemastine may increase the sedative activities of Pramipexole.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Pramipexole is combined with Clevidipine.Approved
ClidiniumClidinium may increase the sedative activities of Pramipexole.Approved
ClobazamClobazam may increase the sedative activities of Pramipexole.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Pramipexole.Approved, Investigational
clomethiazoleclomethiazole may increase the sedative activities of Pramipexole.Investigational
ClomipramineClomipramine may increase the sedative activities of Pramipexole.Approved, Vet Approved
ClonazepamClonazepam may increase the sedative activities of Pramipexole.Approved, Illicit
ClonidineClonidine may increase the sedative activities of Pramipexole.Approved
ClopenthixolClopenthixol may increase the sedative activities of Pramipexole.Experimental
ClorazepateClorazepate may increase the sedative activities of Pramipexole.Approved, Illicit
ClothiapineClothiapine may increase the sedative activities of Pramipexole.Experimental
ClozapineClozapine may increase the sedative activities of Pramipexole.Approved
CocaineCocaine may increase the sedative activities of Pramipexole.Approved, Illicit
CodeineCodeine may increase the sedative activities of Pramipexole.Approved, Illicit
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Pramipexole.Approved, Investigational
CyclizineCyclizine may increase the sedative activities of Pramipexole.Approved
CyclobenzaprineCyclobenzaprine may increase the sedative activities of Pramipexole.Approved
CyproheptadineCyproheptadine may increase the sedative activities of Pramipexole.Approved
DantroleneDantrolene may increase the sedative activities of Pramipexole.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Pramipexole is combined with Dapagliflozin.Approved
DapiprazoleDapiprazole may increase the sedative activities of Pramipexole.Approved
DeramciclaneDeramciclane may increase the sedative activities of Pramipexole.Investigational
DesfluraneDesflurane may increase the sedative activities of Pramipexole.Approved
DesipramineDesipramine may increase the sedative activities of Pramipexole.Approved
DesloratadineDesloratadine may increase the sedative activities of Pramipexole.Approved, Investigational
DetomidineDetomidine may increase the sedative activities of Pramipexole.Vet Approved
DexbrompheniramineDexbrompheniramine may increase the sedative activities of Pramipexole.Approved
DexmedetomidineDexmedetomidine may increase the sedative activities of Pramipexole.Approved, Vet Approved
DextromoramideDextromoramide may increase the sedative activities of Pramipexole.Experimental, Illicit
DextropropoxypheneDextropropoxyphene may increase the sedative activities of Pramipexole.Approved, Illicit, Withdrawn
DezocineDezocine may increase the sedative activities of Pramipexole.Approved
DiazepamDiazepam may increase the sedative activities of Pramipexole.Approved, Illicit, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Pramipexole is combined with Diclofenamide.Approved
Diethyl etherDiethyl ether may increase the sedative activities of Pramipexole.Experimental
DifenoxinDifenoxin may increase the sedative activities of Pramipexole.Approved, Illicit
DihydrocodeineDihydrocodeine may increase the sedative activities of Pramipexole.Approved, Illicit
DihydroetorphineDihydroetorphine may increase the sedative activities of Pramipexole.Experimental, Illicit
DihydromorphineDihydromorphine may increase the sedative activities of Pramipexole.Experimental, Illicit
DiltiazemThe risk or severity of adverse effects can be increased when Pramipexole is combined with Diltiazem.Approved
DimenhydrinateDimenhydrinate may increase the sedative activities of Pramipexole.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Pramipexole is combined with Dinutuximab.Approved
DiphenhydramineDiphenhydramine may increase the sedative activities of Pramipexole.Approved
DiphenoxylateDiphenoxylate may increase the sedative activities of Pramipexole.Approved, Illicit
DipyridamoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Dipyridamole.Approved
DixyrazineDixyrazine may increase the sedative activities of Pramipexole.Experimental
DoramectinDoramectin may increase the sedative activities of Pramipexole.Vet Approved
DoxazosinThe risk or severity of adverse effects can be increased when Pramipexole is combined with Doxazosin.Approved
DoxepinDoxepin may increase the sedative activities of Pramipexole.Approved
DoxylamineDoxylamine may increase the sedative activities of Pramipexole.Approved, Vet Approved
DPDPEDPDPE may increase the sedative activities of Pramipexole.Investigational
DroperidolDroperidol may increase the sedative activities of Pramipexole.Approved, Vet Approved
DrotebanolDrotebanol may increase the sedative activities of Pramipexole.Experimental, Illicit
DuloxetinePramipexole may increase the orthostatic hypotensive activities of Duloxetine.Approved
DyclonineDyclonine may increase the sedative activities of Pramipexole.Approved
EcgonineEcgonine may increase the sedative activities of Pramipexole.Experimental, Illicit
EcopipamEcopipam may increase the sedative activities of Pramipexole.Investigational
EfavirenzEfavirenz may increase the sedative activities of Pramipexole.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Pramipexole.Approved
EltanoloneEltanolone may increase the sedative activities of Pramipexole.Investigational
EmpagliflozinThe risk or severity of adverse effects can be increased when Pramipexole is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Pramipexole is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Pramipexole.Approved
EnfluraneEnflurane may increase the sedative activities of Pramipexole.Approved, Vet Approved
EntacaponeEntacapone may increase the sedative activities of Pramipexole.Approved, Investigational
EplerenoneThe risk or severity of adverse effects can be increased when Pramipexole is combined with Eplerenone.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Pramipexole.Approved
EprosartanThe risk or severity of adverse effects can be increased when Pramipexole is combined with Eprosartan.Approved
EsmololThe risk or severity of adverse effects can be increased when Pramipexole is combined with Esmolol.Approved
EstazolamEstazolam may increase the sedative activities of Pramipexole.Approved, Illicit
EszopicloneEszopiclone may increase the sedative activities of Pramipexole.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Pramipexole is combined with Etacrynic acid.Approved
EthanolEthanol may increase the sedative activities of Pramipexole.Approved
EthchlorvynolEthchlorvynol may increase the sedative activities of Pramipexole.Approved, Illicit, Withdrawn
EthosuximideEthosuximide may increase the sedative activities of Pramipexole.Approved
EthotoinEthotoin may increase the sedative activities of Pramipexole.Approved
Ethyl carbamateEthyl carbamate may increase the sedative activities of Pramipexole.Withdrawn
Ethyl chlorideEthyl chloride may increase the sedative activities of Pramipexole.Experimental
Ethyl loflazepateEthyl loflazepate may increase the sedative activities of Pramipexole.Approved, Illicit
EthylmorphineEthylmorphine may increase the sedative activities of Pramipexole.Approved, Illicit
EtidocaineEtidocaine may increase the sedative activities of Pramipexole.Approved
EtifoxineEtifoxine may increase the sedative activities of Pramipexole.Withdrawn
EtizolamEtizolam may increase the sedative activities of Pramipexole.Approved
EtomidateEtomidate may increase the sedative activities of Pramipexole.Approved
EtorphineEtorphine may increase the sedative activities of Pramipexole.Illicit, Vet Approved
EzogabineEzogabine may increase the sedative activities of Pramipexole.Approved
FelbamateFelbamate may increase the sedative activities of Pramipexole.Approved
FelodipineThe risk or severity of adverse effects can be increased when Pramipexole is combined with Felodipine.Approved, Investigational
FencamfamineFencamfamine may increase the sedative activities of Pramipexole.Approved, Illicit, Withdrawn
FenoldopamThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Pramipexole.Approved
FentanylFentanyl may increase the sedative activities of Pramipexole.Approved, Illicit, Investigational, Vet Approved
FexofenadineFexofenadine may increase the sedative activities of Pramipexole.Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Pramipexole.Approved
FlibanserinFlibanserin may increase the sedative activities of Pramipexole.Approved
FluanisoneFluanisone may increase the sedative activities of Pramipexole.Experimental
FludiazepamFludiazepam may increase the sedative activities of Pramipexole.Approved, Illicit
FlunarizineFlunarizine may increase the sedative activities of Pramipexole.Approved
FlunitrazepamFlunitrazepam may increase the sedative activities of Pramipexole.Approved, Illicit
FlupentixolFlupentixol may increase the sedative activities of Pramipexole.Approved, Withdrawn
FluphenazineFluphenazine may increase the sedative activities of Pramipexole.Approved
FlurazepamFlurazepam may increase the sedative activities of Pramipexole.Approved, Illicit
FluspirileneFluspirilene may increase the sedative activities of Pramipexole.Approved
Fluticasone propionateFluticasone propionate may increase the sedative activities of Pramipexole.Approved
FluvoxamineFluvoxamine may increase the sedative activities of Pramipexole.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Pramipexole is combined with Fosinopril.Approved
FosphenytoinFosphenytoin may increase the sedative activities of Pramipexole.Approved
FospropofolFospropofol may increase the sedative activities of Pramipexole.Approved, Illicit
FurosemideThe risk or severity of adverse effects can be increased when Pramipexole is combined with Furosemide.Approved, Vet Approved
GabapentinGabapentin may increase the sedative activities of Pramipexole.Approved, Investigational
Gabapentin EnacarbilGabapentin Enacarbil may increase the sedative activities of Pramipexole.Approved
Gamma Hydroxybutyric AcidGamma Hydroxybutyric Acid may increase the sedative activities of Pramipexole.Approved, Illicit
GepironeGepirone may increase the sedative activities of Pramipexole.Investigational
GlutethimideGlutethimide may increase the sedative activities of Pramipexole.Approved, Illicit
GuanfacineGuanfacine may increase the sedative activities of Pramipexole.Approved, Investigational
HalazepamHalazepam may increase the sedative activities of Pramipexole.Approved, Illicit, Withdrawn
HaloperidolHaloperidol may increase the sedative activities of Pramipexole.Approved
HalothaneHalothane may increase the sedative activities of Pramipexole.Approved, Vet Approved
HeroinHeroin may increase the sedative activities of Pramipexole.Approved, Illicit
HexobarbitalHexobarbital may increase the sedative activities of Pramipexole.Approved
HydralazineThe risk or severity of adverse effects can be increased when Pramipexole is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Pramipexole is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneHydrocodone may increase the sedative activities of Pramipexole.Approved, Illicit
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Pramipexole.Approved
HydromorphoneHydromorphone may increase the sedative activities of Pramipexole.Approved, Illicit
HydroxyzineHydroxyzine may increase the sedative activities of Pramipexole.Approved
IloperidoneIloperidone may increase the sedative activities of Pramipexole.Approved
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Pramipexole.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Pramipexole.Investigational
ImipramineImipramine may increase the sedative activities of Pramipexole.Approved
IndapamideThe risk or severity of adverse effects can be increased when Pramipexole is combined with Indapamide.Approved
IndiplonIndiplon may increase the sedative activities of Pramipexole.Investigational
IndoraminThe risk or severity of adverse effects can be increased when Indoramin is combined with Pramipexole.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Pramipexole is combined with Irbesartan.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Pramipexole.Approved
IsofluraneIsoflurane may increase the sedative activities of Pramipexole.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Pramipexole is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Pramipexole is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Pramipexole is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Pramipexole is combined with Isradipine.Approved
KetamineKetamine may increase the sedative activities of Pramipexole.Approved, Vet Approved
KetazolamKetazolam may increase the sedative activities of Pramipexole.Approved
KetobemidoneKetobemidone may increase the sedative activities of Pramipexole.Approved
LabetalolThe risk or severity of adverse effects can be increased when Pramipexole is combined with Labetalol.Approved
LacidipineThe risk or severity of adverse effects can be increased when Lacidipine is combined with Pramipexole.Approved
LamotrigineLamotrigine may increase the sedative activities of Pramipexole.Approved, Investigational
LercanidipineThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Pramipexole.Approved, Investigational
LevetiracetamLevetiracetam may increase the sedative activities of Pramipexole.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Pramipexole is combined with Levobunolol.Approved
LevobupivacaineLevobupivacaine may increase the sedative activities of Pramipexole.Approved
LevocabastineLevocabastine may increase the sedative activities of Pramipexole.Approved
LevocetirizineLevocetirizine may increase the sedative activities of Pramipexole.Approved
LevodopaLevodopa may increase the sedative activities of Pramipexole.Approved
Levomethadyl AcetateLevomethadyl Acetate may increase the sedative activities of Pramipexole.Approved
LevorphanolLevorphanol may increase the sedative activities of Pramipexole.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Pramipexole.Approved, Investigational
LidocaineLidocaine may increase the sedative activities of Pramipexole.Approved, Vet Approved
LisinoprilThe risk or severity of adverse effects can be increased when Pramipexole is combined with Lisinopril.Approved, Investigational
LithiumLithium may increase the sedative activities of Pramipexole.Approved
LofentanilLofentanil may increase the sedative activities of Pramipexole.Illicit
LofexidineThe risk or severity of adverse effects can be increased when Lofexidine is combined with Pramipexole.Approved, Investigational
LoprazolamLoprazolam may increase the sedative activities of Pramipexole.Experimental
LoratadineLoratadine may increase the sedative activities of Pramipexole.Approved
LorazepamLorazepam may increase the sedative activities of Pramipexole.Approved
LormetazepamLormetazepam may increase the sedative activities of Pramipexole.Approved
LosartanThe risk or severity of adverse effects can be increased when Pramipexole is combined with Losartan.Approved
LoxapineLoxapine may increase the sedative activities of Pramipexole.Approved
LumateperoneThe therapeutic efficacy of Pramipexole can be decreased when used in combination with Lumateperone.Investigational
LurasidoneLurasidone may increase the sedative activities of Pramipexole.Approved
Magnesium SulfateMagnesium Sulfate may increase the sedative activities of Pramipexole.Approved, Vet Approved
MannitolThe risk or severity of adverse effects can be increased when Pramipexole is combined with Mannitol.Approved, Investigational
MaprotilineMaprotiline may increase the sedative activities of Pramipexole.Approved
MebicarMebicar may increase the sedative activities of Pramipexole.Experimental
MecamylamineThe risk or severity of adverse effects can be increased when Pramipexole is combined with Mecamylamine.Approved
MeclizineMeclizine may increase the sedative activities of Pramipexole.Approved
MedazepamMedazepam may increase the sedative activities of Pramipexole.Experimental
MedetomidineMedetomidine may increase the sedative activities of Pramipexole.Vet Approved
MelatoninMelatonin may increase the sedative activities of Pramipexole.Approved, Nutraceutical, Vet Approved
MelperoneMelperone may increase the sedative activities of Pramipexole.Approved
MepivacaineMepivacaine may increase the sedative activities of Pramipexole.Approved, Vet Approved
MeprobamateMeprobamate may increase the sedative activities of Pramipexole.Approved, Illicit
MeptazinolMeptazinol may increase the sedative activities of Pramipexole.Experimental
MesoridazineMesoridazine may increase the sedative activities of Pramipexole.Approved
MetaxaloneMetaxalone may increase the sedative activities of Pramipexole.Approved
MethadoneMethadone may increase the sedative activities of Pramipexole.Approved
Methadyl AcetateMethadyl Acetate may increase the sedative activities of Pramipexole.Approved, Illicit
MethapyrileneMethapyrilene may increase the sedative activities of Pramipexole.Withdrawn
MethaqualoneMethaqualone may increase the sedative activities of Pramipexole.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Pramipexole is combined with Methazolamide.Approved
MethocarbamolMethocarbamol may increase the sedative activities of Pramipexole.Approved, Vet Approved
MethohexitalMethohexital may increase the sedative activities of Pramipexole.Approved
MethotrimeprazineMethotrimeprazine may increase the sedative activities of Pramipexole.Approved
MethoxyfluraneMethoxyflurane may increase the sedative activities of Pramipexole.Approved, Vet Approved
MethsuximideMethsuximide may increase the sedative activities of Pramipexole.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Pramipexole is combined with Methyclothiazide.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Pramipexole is combined with Methyldopa.Approved
MethylecgonineMethylecgonine may increase the sedative activities of Pramipexole.Experimental
MethylphenidateThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Pramipexole.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the sedative activities of Pramipexole.Approved
MetipranololThe risk or severity of adverse effects can be increased when Pramipexole is combined with Metipranolol.Approved
MetoclopramideThe therapeutic efficacy of Pramipexole can be decreased when used in combination with Metoclopramide.Approved, Investigational
MetolazoneThe risk or severity of adverse effects can be increased when Pramipexole is combined with Metolazone.Approved
MetoprololThe risk or severity of adverse effects can be increased when Pramipexole is combined with Metoprolol.Approved, Investigational
MidazolamMidazolam may increase the sedative activities of Pramipexole.Approved, Illicit
MinoxidilThe risk or severity of adverse effects can be increased when Pramipexole is combined with Minoxidil.Approved
MirtazapineMirtazapine may increase the sedative activities of Pramipexole.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Pramipexole is combined with Moexipril.Approved
MolindoneMolindone may increase the sedative activities of Pramipexole.Approved
MorphineMorphine may increase the sedative activities of Pramipexole.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Moxonidine is combined with Pramipexole.Approved
NabiloneNabilone may increase the sedative activities of Pramipexole.Approved, Investigational
NadololThe risk or severity of adverse effects can be increased when Pramipexole is combined with Nadolol.Approved
NalbuphineNalbuphine may increase the sedative activities of Pramipexole.Approved
NebivololThe risk or severity of adverse effects can be increased when Pramipexole is combined with Nebivolol.Approved, Investigational
NesiritideThe risk or severity of adverse effects can be increased when Pramipexole is combined with Nesiritide.Approved, Investigational
NicardipineThe risk or severity of adverse effects can be increased when Pramipexole is combined with Nicardipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Pramipexole.Approved
NifedipineThe risk or severity of adverse effects can be increased when Pramipexole is combined with Nifedipine.Approved
NilvadipineThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Pramipexole.Approved
NimodipineThe risk or severity of adverse effects can be increased when Pramipexole is combined with Nimodipine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Pramipexole is combined with Nisoldipine.Approved
NitrazepamNitrazepam may increase the sedative activities of Pramipexole.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Pramipexole.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Pramipexole.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Pramipexole is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Pramipexole is combined with Nitroprusside.Approved
Nitrous oxideNitrous oxide may increase the sedative activities of Pramipexole.Approved, Vet Approved
NorfluraneNorflurane may increase the sedative activities of Pramipexole.Investigational
NormethadoneNormethadone may increase the sedative activities of Pramipexole.Approved, Illicit
NortriptylineNortriptyline may increase the sedative activities of Pramipexole.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Pramipexole.Approved
OlanzapineOlanzapine may increase the sedative activities of Pramipexole.Approved, Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Pramipexole is combined with Olmesartan.Approved, Investigational
OlopatadineOlopatadine may increase the sedative activities of Pramipexole.Approved
OndansetronOndansetron may increase the sedative activities of Pramipexole.Approved
OpiumOpium may increase the sedative activities of Pramipexole.Approved, Illicit
OrphenadrineOrphenadrine may increase the sedative activities of Pramipexole.Approved
OsanetantOsanetant may increase the sedative activities of Pramipexole.Investigational
OxazepamOxazepam may increase the sedative activities of Pramipexole.Approved
OxethazaineOxethazaine may increase the sedative activities of Pramipexole.Investigational
OxprenololOxprenolol may increase the sedative activities of Pramipexole.Approved
OxybuprocaineOxybuprocaine may increase the sedative activities of Pramipexole.Approved
OxycodoneOxycodone may increase the sedative activities of Pramipexole.Approved, Illicit, Investigational
OxymorphoneOxymorphone may increase the sedative activities of Pramipexole.Approved, Investigational, Vet Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Pramipexole.Approved, Vet Approved
PaliperidonePaliperidone may increase the sedative activities of Pramipexole.Approved
PapaverineThe risk or severity of adverse effects can be increased when Pramipexole is combined with Papaverine.Approved
ParaldehydeParaldehyde may increase the sedative activities of Pramipexole.Approved
PenbutololThe risk or severity of adverse effects can be increased when Pramipexole is combined with Penbutolol.Approved, Investigational
PenfluridolPenfluridol may increase the sedative activities of Pramipexole.Experimental
PentazocinePentazocine may increase the sedative activities of Pramipexole.Approved, Vet Approved
PentobarbitalPentobarbital may increase the sedative activities of Pramipexole.Approved, Vet Approved
PerampanelPerampanel may increase the sedative activities of Pramipexole.Approved
PerazinePerazine may increase the sedative activities of Pramipexole.Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Pramipexole is combined with Perindopril.Approved
PerospironePerospirone may increase the sedative activities of Pramipexole.Approved
PerphenazinePerphenazine may increase the sedative activities of Pramipexole.Approved
PethidinePethidine may increase the sedative activities of Pramipexole.Approved
PhenazocinePhenazocine may increase the sedative activities of Pramipexole.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Pramipexole.Approved
PhenibutPhenibut may increase the sedative activities of Pramipexole.Experimental
PhenobarbitalPhenobarbital may increase the sedative activities of Pramipexole.Approved
PhenoperidinePhenoperidine may increase the sedative activities of Pramipexole.Experimental
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Pramipexole.Approved
PhenoxyethanolPhenoxyethanol may increase the sedative activities of Pramipexole.Approved
PhentolamineThe risk or severity of adverse effects can be increased when Phentolamine is combined with Pramipexole.Approved
PhenytoinPhenytoin may increase the sedative activities of Pramipexole.Approved, Vet Approved
PimavanserinThe therapeutic efficacy of Pramipexole can be decreased when used in combination with Pimavanserin.Investigational
PimozidePimozide may increase the sedative activities of Pramipexole.Approved
PindololThe risk or severity of adverse effects can be increased when Pramipexole is combined with Pindolol.Approved
PipamperonePipamperone may increase the sedative activities of Pramipexole.Approved
PipotiazinePipotiazine may increase the sedative activities of Pramipexole.Approved
PiritramidePiritramide may increase the sedative activities of Pramipexole.Investigational
PizotifenPizotifen may increase the sedative activities of Pramipexole.Approved
PomalidomidePomalidomide may increase the sedative activities of Pramipexole.Approved
PramocainePramocaine may increase the sedative activities of Pramipexole.Approved
PrazepamPrazepam may increase the sedative activities of Pramipexole.Approved, Illicit
PrazosinThe risk or severity of adverse effects can be increased when Pramipexole is combined with Prazosin.Approved
PregabalinPregabalin may increase the sedative activities of Pramipexole.Approved, Illicit, Investigational
PrilocainePrilocaine may increase the sedative activities of Pramipexole.Approved
PrimidonePrimidone may increase the sedative activities of Pramipexole.Approved, Vet Approved
ProcaineProcaine may increase the sedative activities of Pramipexole.Approved, Investigational, Vet Approved
ProchlorperazineProchlorperazine may increase the sedative activities of Pramipexole.Approved, Vet Approved
PromazinePromazine may increase the sedative activities of Pramipexole.Approved, Vet Approved
PromethazinePromethazine may increase the sedative activities of Pramipexole.Approved
PropanididPropanidid may increase the sedative activities of Pramipexole.Experimental
ProparacaineProparacaine may increase the sedative activities of Pramipexole.Approved, Vet Approved
PropericiazineThe therapeutic efficacy of Propericiazine can be decreased when used in combination with Pramipexole.Approved
PropofolPropofol may increase the sedative activities of Pramipexole.Approved, Investigational, Vet Approved
PropoxycainePropoxycaine may increase the sedative activities of Pramipexole.Approved
PropranololThe risk or severity of adverse effects can be increased when Pramipexole is combined with Propranolol.Approved, Investigational
ProtriptylineProtriptyline may increase the sedative activities of Pramipexole.Approved
ProxibarbalProxibarbal may increase the sedative activities of Pramipexole.Experimental
PSD502PSD502 may increase the sedative activities of Pramipexole.Investigational
QuazepamQuazepam may increase the sedative activities of Pramipexole.Approved, Illicit
QuetiapineQuetiapine may increase the sedative activities of Pramipexole.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Pramipexole is combined with Quinapril.Approved, Investigational
QuinisocaineQuinisocaine may increase the sedative activities of Pramipexole.Experimental
RacloprideRaclopride may increase the sedative activities of Pramipexole.Investigational
RamelteonRamelteon may increase the sedative activities of Pramipexole.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Pramipexole is combined with Ramipril.Approved
RasagilineThe risk or severity of adverse effects can be increased when Pramipexole is combined with Rasagiline.Approved
RemifentanilRemifentanil may increase the sedative activities of Pramipexole.Approved
RemoxiprideRemoxipride may increase the sedative activities of Pramipexole.Approved, Withdrawn
ReserpineReserpine may increase the sedative activities of Pramipexole.Approved
RiociguatThe risk or severity of adverse effects can be increased when Pramipexole is combined with Riociguat.Approved
RisperidoneRisperidone may increase the sedative activities of Pramipexole.Approved, Investigational
RitanserinRitanserin may increase the sedative activities of Pramipexole.Investigational
RomifidineRomifidine may increase the sedative activities of Pramipexole.Vet Approved
RopiniroleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Ropinirole.Approved, Investigational
RopivacaineRopivacaine may increase the sedative activities of Pramipexole.Approved
RotigotineThe risk or severity of adverse effects can be increased when Pramipexole is combined with Rotigotine.Approved
RP5063The therapeutic efficacy of Pramipexole can be decreased when used in combination with RP5063.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Pramipexole is combined with Sacubitril.Approved
ScopolamineScopolamine may increase the sedative activities of Pramipexole.Approved
SecobarbitalSecobarbital may increase the sedative activities of Pramipexole.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Pramipexole is combined with Selegiline.Approved, Investigational, Vet Approved
SepranoloneSepranolone may increase the sedative activities of Pramipexole.Investigational
SertindoleSertindole may increase the sedative activities of Pramipexole.Approved, Withdrawn
SevofluraneSevoflurane may increase the sedative activities of Pramipexole.Approved, Vet Approved
Sodium NitriteThe risk or severity of adverse effects can be increased when Pramipexole is combined with Sodium Nitrite.Approved
Sodium oxybateSodium oxybate may increase the sedative activities of Pramipexole.Approved
SotalolThe risk or severity of adverse effects can be increased when Pramipexole is combined with Sotalol.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Pramipexole is combined with Spironolactone.Approved
StiripentolStiripentol may increase the sedative activities of Pramipexole.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Pramipexole is combined with Streptokinase.Approved
SufentanilSufentanil may increase the sedative activities of Pramipexole.Approved, Investigational
SulpirideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Pramipexole.Approved
SultoprideSultopride may increase the sedative activities of Pramipexole.Experimental
SuvorexantSuvorexant may increase the sedative activities of Pramipexole.Approved
TamsulosinThe risk or severity of adverse effects can be increased when Pramipexole is combined with Tamsulosin.Approved, Investigational
TandospironeTandospirone may increase the sedative activities of Pramipexole.Investigational
TapentadolTapentadol may increase the sedative activities of Pramipexole.Approved
TasimelteonTasimelteon may increase the sedative activities of Pramipexole.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Pramipexole is combined with Telmisartan.Approved, Investigational
TemazepamTemazepam may increase the sedative activities of Pramipexole.Approved
TerazosinThe risk or severity of adverse effects can be increased when Pramipexole is combined with Terazosin.Approved
TetrabenazineTetrabenazine may increase the sedative activities of Pramipexole.Approved
TetracaineTetracaine may increase the sedative activities of Pramipexole.Approved, Vet Approved
TetrahydropalmatineTetrahydropalmatine may increase the sedative activities of Pramipexole.Investigational
TetrodotoxinTetrodotoxin may increase the sedative activities of Pramipexole.Investigational
ThalidomideThalidomide may increase the sedative activities of Pramipexole.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the sedative activities of Pramipexole.Approved, Vet Approved
ThiopentalThiopental may increase the sedative activities of Pramipexole.Approved, Vet Approved
ThioproperazineThe therapeutic efficacy of Thioproperazine can be decreased when used in combination with Pramipexole.Approved
ThioridazineThioridazine may increase the sedative activities of Pramipexole.Withdrawn
ThiothixeneThiothixene may increase the sedative activities of Pramipexole.Approved
TiagabineTiagabine may increase the sedative activities of Pramipexole.Approved
TiaprideTiapride may increase the sedative activities of Pramipexole.Approved, Investigational
TiletamineTiletamine may increase the sedative activities of Pramipexole.Vet Approved
TilidineTilidine may increase the sedative activities of Pramipexole.Experimental
TimololThe risk or severity of adverse effects can be increased when Pramipexole is combined with Timolol.Approved
TizanidineTizanidine may increase the sedative activities of Pramipexole.Approved
TolazolineThe risk or severity of adverse effects can be increased when Pramipexole is combined with Tolazoline.Approved, Vet Approved
TolcaponeTolcapone may increase the sedative activities of Pramipexole.Approved, Withdrawn
TopiramateTopiramate may increase the sedative activities of Pramipexole.Approved
TorasemideThe risk or severity of adverse effects can be increased when Pramipexole is combined with Torasemide.Approved
TramadolTramadol may increase the sedative activities of Pramipexole.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Pramipexole is combined with Trandolapril.Approved
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the sedative activities of Pramipexole.Experimental
TranylcypromineTranylcypromine may increase the sedative activities of Pramipexole.Approved
TrazodoneTrazodone may increase the sedative activities of Pramipexole.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Pramipexole is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Pramipexole is combined with Triamterene.Approved
TriazolamTriazolam may increase the sedative activities of Pramipexole.Approved
Tricaine methanesulfonateTricaine methanesulfonate may increase the sedative activities of Pramipexole.Vet Approved
TrichloroethyleneTrichloroethylene may increase the sedative activities of Pramipexole.Experimental
TrifluoperazineTrifluoperazine may increase the sedative activities of Pramipexole.Approved
TrifluperidolTrifluperidol may increase the sedative activities of Pramipexole.Experimental
TriflupromazineTriflupromazine may increase the sedative activities of Pramipexole.Approved, Vet Approved
TrimipramineTrimipramine may increase the sedative activities of Pramipexole.Approved
TriprolidineTriprolidine may increase the sedative activities of Pramipexole.Approved
Valproic AcidValproic Acid may increase the sedative activities of Pramipexole.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Pramipexole is combined with Valsartan.Approved, Investigational
VeraliprideVeralipride may increase the sedative activities of Pramipexole.Experimental
VerapamilThe risk or severity of adverse effects can be increased when Pramipexole is combined with Verapamil.Approved
VigabatrinVigabatrin may increase the sedative activities of Pramipexole.Approved
Vinyl etherVinyl ether may increase the sedative activities of Pramipexole.Experimental
VortioxetineVortioxetine may increase the sedative activities of Pramipexole.Approved
XenonXenon may increase the sedative activities of Pramipexole.Experimental
XylazineXylazine may increase the sedative activities of Pramipexole.Vet Approved
ZaleplonZaleplon may increase the sedative activities of Pramipexole.Approved, Illicit, Investigational
ZiconotideZiconotide may increase the sedative activities of Pramipexole.Approved
ZiprasidoneZiprasidone may increase the sedative activities of Pramipexole.Approved
ZolazepamZolazepam may increase the sedative activities of Pramipexole.Vet Approved
ZolpidemZolpidem may increase the sedative activities of Pramipexole.Approved
ZonisamideZonisamide may increase the sedative activities of Pramipexole.Approved, Investigational
ZopicloneZopiclone may increase the sedative activities of Pramipexole.Approved
ZotepineZotepine may increase the sedative activities of Pramipexole.Approved
ZuclopenthixolZuclopenthixol may increase the sedative activities of Pramipexole.Approved, Investigational
Food Interactions
  • Take without regard to meals, however if nausea is a problem, taking the product with food may reduce its incidence.

References

Synthesis Reference
US4886812
General References
  1. Mierau J, Schneider FJ, Ensinger HA, Chio CL, Lajiness ME, Huff RM: Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors. Eur J Pharmacol. 1995 Jun 23;290(1):29-36. [PubMed:7664822 ]
External Links
Human Metabolome Database
HMDB14557
KEGG Drug
D00559
PubChem Compound
119570
PubChem Substance
46505897
ChemSpider
106770
BindingDB
50116766
ChEBI
8356
ChEMBL
CHEMBL301265
Therapeutic Targets Database
DAP000019
PharmGKB
PA164742949
IUPHAR
953
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Pramipexole
ATC Codes
N04BC05 — Pramipexole
AHFS Codes
  • 28:36.20.08
PDB Entries
Not Available
FDA label
Not Available
MSDS
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableCocaine Abuse / Dependence, Cocaine / Substance Abuse1
1CompletedNot AvailableHealthy Volunteers2
1CompletedTreatmentHealthy Volunteers5
1CompletedTreatmentObsessive-Compulsive Disorder (OCD)1
1CompletedTreatmentParkinson's Disease (PD)1
2CompletedDiagnosticParkinson's Disease (PD) / Parkinsonian Syndromes1
2CompletedTreatmentBipolar Disorder (BD)1
2CompletedTreatmentDepression, Bipolar1
2CompletedTreatmentGilles de la Tourette's Syndrome1
2CompletedTreatmentMajor Depressive Disorder (MDD)1
2CompletedTreatmentRestless Legs Syndrome (RLS)2
2TerminatedTreatmentAdvanced Stage Parkinson's Disease1
2TerminatedTreatmentFibromyalgia1
2Unknown StatusTreatmentParkinson's Disease (PD)1
2, 3CompletedTreatmentParkinson's Disease (PD)1
3CompletedTreatmentEarly Parkinson Disease (Early PD)1
3CompletedTreatmentEarly Stage Parkinson's Disease1
3CompletedTreatmentIdiopathic Parkinson's Disease1
3CompletedTreatmentIdiopathic Restless Legs Syndrome2
3CompletedTreatmentParkinson's Disease (PD)10
3CompletedTreatmentRestless Legs Syndrome (RLS)6
3Not Yet RecruitingTreatmentTremor, Essential1
3Unknown StatusTreatmentSchizoaffective Disorders / Schizophrenic Disorders1
3WithdrawnTreatmentBinge Eating Disorder (BED)1
4CompletedNot AvailableDepressive State / Parkinson's Disease (PD)1
4CompletedNot AvailableParkinson's Disease (PD)1
4CompletedDiagnosticParkinson's Disease (PD)1
4CompletedOtherRestless Legs Syndrome (RLS)1
4CompletedTreatmentBipolar Disorder (BD)1
4CompletedTreatmentDepressive State2
4CompletedTreatmentDepressive State / Parkinson's Disease (PD)1
4CompletedTreatmentDepressive State / Restless Legs Syndrome (RLS)1
4CompletedTreatmentParkinson's Disease (PD)4
4CompletedTreatmentRestless Legs Syndrome (RLS)4
4RecruitingTreatmentBipolar Disorder (BD)1
4RecruitingTreatmentMajor Depressive Disorder (MDD)1
4SuspendedTreatmentHealthy Volunteers1
4TerminatedTreatmentEarly-Stage Parkinson's Disease1
4Unknown StatusTreatmentParkinson's Disease (PD)1
Not AvailableCompletedNot AvailableHealthy Volunteers1
Not AvailableCompletedNot AvailableHeart Failure, Unspecified1
Not AvailableCompletedNot AvailableParkinson's Disease (PD)9
Not AvailableCompletedNot AvailableRestless Legs Syndrome (RLS)3
Not AvailableCompletedTreatmentIdiopathic Parkinson's Disease1
Not AvailableRecruitingNot AvailableAtypical Parkinson Disease / Corticobasal Degeneration / Gait, Frontal / Multiple System Atrophy (MSA) / Parkinson's Disease (PD) / Parkinsonian Disorders / Progressive Supranuclear Palsy (PSP)1

Pharmacoeconomics

Manufacturers
  • Boehringer ingelheim
Packagers
Dosage forms
FormRouteStrength
TabletOral0.75 mg
TabletOral0.125 mg
TabletOral0.25 mg
TabletOral0.5 mg
TabletOral1.0 mg
TabletOral1.5 mg
Tablet, extended releaseOral.375 mg/1
Tablet, extended releaseOral.75 mg/1
Tablet, extended releaseOral1.5 mg/1
Tablet, extended releaseOral2.25 mg/1
Tablet, extended releaseOral3 mg/1
Tablet, extended releaseOral3.75 mg/1
Tablet, extended releaseOral4.5 mg/1
TabletOral0.088 mg
TabletOral0.18 mg
TabletOral0.35 mg
TabletOral0.7 mg
TabletOral1.1 mg
Tablet, extended releaseOral0.26 mg
Tablet, extended releaseOral0.52 mg
Tablet, extended releaseOral1.05 mg
Tablet, extended releaseOral1.57 mg
Tablet, extended releaseOral2.1 mg
Tablet, extended releaseOral2.62 mg
Tablet, extended releaseOral3.15 mg
TabletOral0.50 mg
TabletOral1 mg
TabletOral.125 mg/1
TabletOral.25 mg/1
TabletOral.5 mg/1
TabletOral.75 mg/1
TabletOral1 mg/1
TabletOral1.5 mg/1
Prices
Unit descriptionCostUnit
Mirapex er 0.375 mg tablet9.83USD tablet
Mirapex er 0.75 mg tablet9.83USD tablet
Mirapex er 1.5 mg tablet9.83USD tablet
Mirapex er 3 mg tablet9.83USD tablet
Mirapex er 4.5 mg tablet9.83USD tablet
Mirapex 0.125 mg tablet3.48USD tablet
Mirapex 0.25 mg tablet3.42USD tablet
Mirapex 0.5 mg tablet3.42USD tablet
Mirapex 1 mg tablet3.42USD tablet
Mirapex 1.5 mg tablet3.42USD tablet
Mirapex 0.75 mg tablet3.28USD tablet
Pramipexole Dihydrochloride 0.125 mg tablet3.07USD tablet
Pramipexole Dihydrochloride 0.25 mg tablet3.07USD tablet
Pramipexole Dihydrochloride 0.5 mg tablet3.07USD tablet
Pramipexole Dihydrochloride 1 mg tablet3.07USD tablet
Pramipexole Dihydrochloride 1.5 mg tablet3.07USD tablet
Pramipexole di-hcl 0.125 mg tablet2.95USD tablet
Pramipexole di-hcl 0.25 mg tablet2.95USD tablet
Pramipexole di-hcl 0.5 mg tablet2.95USD tablet
Pramipexole di-hcl 1 mg tablet2.95USD tablet
Pramipexole di-hcl 1.5 mg tablet2.95USD tablet
Mirapex 1 mg Tablet2.2USD tablet
Mirapex 1.5 mg Tablet2.2USD tablet
Apo-Pramipexole 1 mg Tablet1.23USD tablet
Apo-Pramipexole 1.5 mg Tablet1.23USD tablet
Co Pramipexole 1 mg Tablet1.23USD tablet
Co Pramipexole 1.5 mg Tablet1.23USD tablet
Novo-Pramipexole 1 mg Tablet1.23USD tablet
Novo-Pramipexole 1.5 mg Tablet1.23USD tablet
Pms-Pramipexole 1 mg Tablet1.23USD tablet
Pms-Pramipexole 1.5 mg Tablet1.23USD tablet
Sandoz Pramipexole 1 mg Tablet1.23USD tablet
Sandoz Pramipexole 1.5 mg Tablet1.23USD tablet
Mirapex 0.25 mg Tablet1.1USD tablet
Apo-Pramipexole 0.25 mg Tablet0.62USD tablet
Co Pramipexole 0.25 mg Tablet0.62USD tablet
Novo-Pramipexole 0.25 mg Tablet0.62USD tablet
Pms-Pramipexole 0.25 mg Tablet0.62USD tablet
Sandoz Pramipexole 0.25 mg Tablet0.62USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US4886812 No1993-10-082010-10-08Us
CA2275379 No2006-11-282018-01-16Canada
US6001861 No1998-01-162018-01-16Us
US6194445 No1998-01-162018-01-16Us
US8679533 No2009-09-082029-09-08Us
US7695734 No2008-04-262028-04-26Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
logP0.4Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.14 mg/mLALOGPS
logP2.18ALOGPS
logP1.76ChemAxon
logS-3.2ALOGPS
pKa (Strongest Acidic)17.66ChemAxon
pKa (Strongest Basic)10.31ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area50.94 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity59.77 m3·mol-1ChemAxon
Polarizability24.47 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9967
Blood Brain Barrier+0.9631
Caco-2 permeable-0.6419
P-glycoprotein substrateSubstrate0.6384
P-glycoprotein inhibitor INon-inhibitor0.842
P-glycoprotein inhibitor IINon-inhibitor0.7464
Renal organic cation transporterNon-inhibitor0.6788
CYP450 2C9 substrateNon-substrate0.8524
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.7558
CYP450 1A2 substrateInhibitor0.9179
CYP450 2C9 inhibitorNon-inhibitor0.7353
CYP450 2D6 inhibitorInhibitor0.5364
CYP450 2C19 inhibitorInhibitor0.586
CYP450 3A4 inhibitorNon-inhibitor0.6708
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7797
Ames testNon AMES toxic0.8133
CarcinogenicityNon-carcinogens0.915
BiodegradationNot ready biodegradable0.9255
Rat acute toxicity2.8676 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8732
hERG inhibition (predictor II)Non-inhibitor0.8397
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of chemical entities known as aralkylamines. These are alkylamines in which the alkyl group is substituted at one carbon atom by an aromatic hydrocarbyl group.
Kingdom
Chemical entities
Super Class
Organic compounds
Class
Organic nitrogen compounds
Sub Class
Organonitrogen compounds
Direct Parent
Aralkylamines
Alternative Parents
Thiazoles / Heteroaromatic compounds / Isothioureas / Dialkylamines / Azacyclic compounds / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Aralkylamine / Heteroaromatic compound / Thiazole / Azole / Isothiourea / Azacycle / Organoheterocyclic compound / Secondary amine / Secondary aliphatic amine / Organopnictogen compound
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
benzothiazoles, diamine (CHEBI:8356 )

Targets

Details
1. D(3) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name
DRD3
Uniprot ID
P35462
Uniprot Name
D(3) dopamine receptor
Molecular Weight
44224.335 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132 ]
  3. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988 ]
Details
2. D(2) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132 ]
  3. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988 ]
Details
3. D(4) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Sh3 domain binding
Specific Function
Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Its activity is mediated by G proteins ...
Gene Name
DRD4
Uniprot ID
P21917
Uniprot Name
D(4) dopamine receptor
Molecular Weight
48359.86 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132 ]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Unknown
General Function
Epinephrine binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine...
Gene Name
ADRA2B
Uniprot ID
P18089
Uniprot Name
Alpha-2B adrenergic receptor
Molecular Weight
49565.8 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132 ]
  2. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988 ]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Unknown
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers...
Gene Name
HTR1A
Uniprot ID
P08908
Uniprot Name
5-hydroxytryptamine receptor 1A
Molecular Weight
46106.335 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132 ]
  2. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988 ]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Unknown
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive subst...
Gene Name
HTR1D
Uniprot ID
P28221
Uniprot Name
5-hydroxytryptamine receptor 1D
Molecular Weight
41906.38 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132 ]
  2. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988 ]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Partial agonist
General Function
Thioesterase binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazo...
Gene Name
ADRA2A
Uniprot ID
P08913
Uniprot Name
Alpha-2A adrenergic receptor
Molecular Weight
48956.275 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132 ]
  2. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988 ]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Unknown
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive subst...
Gene Name
HTR1B
Uniprot ID
P28222
Uniprot Name
5-hydroxytryptamine receptor 1B
Molecular Weight
43567.535 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132 ]
  2. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988 ]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Unknown
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
Gene Name
HTR2A
Uniprot ID
P28223
Uniprot Name
5-hydroxytryptamine receptor 2A
Molecular Weight
52602.58 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132 ]
  2. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988 ]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Unknown
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various ergot alkaloid derivatives and psychoactive substances. Ligand binding causes a conformation...
Gene Name
HTR2B
Uniprot ID
P41595
Uniprot Name
5-hydroxytryptamine receptor 2B
Molecular Weight
54297.41 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132 ]
  2. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988 ]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Unknown
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-...
Gene Name
HTR2C
Uniprot ID
P28335
Uniprot Name
5-hydroxytryptamine receptor 2C
Molecular Weight
51820.705 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132 ]
  2. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988 ]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Unknown
General Function
Protein homodimerization activity
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name
ADRA2C
Uniprot ID
P18825
Uniprot Name
Alpha-2C adrenergic receptor
Molecular Weight
49521.585 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132 ]
  2. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988 ]
Details
13. D(1A) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Unknown
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name
DRD1
Uniprot ID
P21728
Uniprot Name
D(1A) dopamine receptor
Molecular Weight
49292.765 Da
References
  1. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988 ]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Unknown
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name
DRD5
Uniprot ID
P21918
Uniprot Name
D(1B) dopamine receptor
Molecular Weight
52950.5 Da
References
  1. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Quaternary ammonium group transmembrane transporter activity
Specific Function
Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creat...
Gene Name
SLC22A2
Uniprot ID
O15244
Uniprot Name
Solute carrier family 22 member 2
Molecular Weight
62579.99 Da
References
  1. Ishiguro N, Saito A, Yokoyama K, Morikawa M, Igarashi T, Tamai I: Transport of the dopamine D2 agonist pramipexole by rat organic cation transporters OCT1 and OCT2 in kidney. Drug Metab Dispos. 2005 Apr;33(4):495-9. Epub 2005 Jan 7. [PubMed:15640376 ]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Secondary active organic cation transmembrane transporter activity
Specific Function
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnico...
Gene Name
SLC22A1
Uniprot ID
O15245
Uniprot Name
Solute carrier family 22 member 1
Molecular Weight
61153.345 Da
References
  1. Ishiguro N, Saito A, Yokoyama K, Morikawa M, Igarashi T, Tamai I: Transport of the dopamine D2 agonist pramipexole by rat organic cation transporters OCT1 and OCT2 in kidney. Drug Metab Dispos. 2005 Apr;33(4):495-9. Epub 2005 Jan 7. [PubMed:15640376 ]

Drug created on June 13, 2005 07:24 / Updated on October 02, 2017 04:36